A Cohort Study Comparing Effectiveness and Safety of Direct Oral Anticoagulants (DOAC) with Vitamin-K Antagonists in Patients with Non-Valvular Atrial Fibrillation (NVAF): Nationwide French Claims and Hospitalization Database (SNIIRAM)
Latest Information Update: 26 May 2020
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Vitamin K antagonists
- Indications Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 30 Mar 2020 Results (n=56403) of dabigatran compared to rivaroxaban, presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology.
- 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
- 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology